An ideal partner for all stages of your translational research
Reithera srl is a company devoted to develop and produce biopharmaceutical products based on gene delivery technologies for advanced therapies, in order to prevent and treat several serious or life-threatening diseases.
The building block of our success
Unlocking the potential
of ground-breaking projects
of ground-breaking projects
Reithera benefits from Okairos´ experienced team, which pioneered the development, manufacture and early clinical testing of non-human origin adeno-vectored vaccines for major infectious diseases such as hepatitis C, malaria, HIV, respiratory syncytial virus, and Ebola. When Okairos was acquired by GlaxoSmithKline (“GSK”) in May 2013, the name of the company was changed to Reithera Srl.
With fully-equipped, state of the art R&D laboratories and GMP production facility located in Rome, and auxiliary laboratories in Naples, Reithera delivers reliable solutions at every step of early development to engineering and industrial process. From early development to final QP release, we provide tailored and effective solutions to meet the industry’s demanding regulatory standards and the expectations of the fast-growing market of gene-delivery technologies.
By innovating on gene delivery systems, manufacturing methods, and step-ahead regulatory compliance strategies, we continue — in seamless cooperation with our partners and clients, as well through our own R&D projects — to fulfill the requirements and exceed the challenges of this new and still untapped field.
Empowering technology and manufacturing of modern medicines
The growth of gene delivery technologies is at the core of a healthcare revolution – a step beyond one-size-fits-all approaches with the potential for individualized treatments. Over the past few decades, increased understanding of immunology and genomics has generated an unprecedented amount of biological information, which scientists are now beginning to translate into new life saving medicines.
Reithera made significant improvements in viral vector engineering, from biological questions faced in early-stage research, to challenges of manufacturing and commercializing such therapies. Viral vector manufacturing portfolio currently includes human and primate adenoviruses, Adeno-Associated Viruses (AAV) and MVA. Our scientists are continuously working on groundbreaking projects with the purpose of empowering viral-vectored technology for next-generation immunotherapeutic and gene therapy products.
We believe that optimal engineering, process development and GMP manufacturing will place viral vector-based therapy at the forefront of modern medicine.
Our state-of-the-art and fully-equipped facilities can satisfy even the highest demand regarding the development, manufacture, and storage of viral vectors, drugs, and clinical samples.
We exploit the high potency of gene delivery technologies using viral vectors to boost T-cell and B-cell immune response against several major diseases.
Get in touch with our team. We will be in contact soon.
Please contact us for any inquiry
Keep updated on Reithera’s activities
- Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adultsOriginally published on Journal of Infection 2019 Feb 8. pii: S0163-4453(19)30038-6. doi: 10.1016/j.jinf.2019.02.003. Green CA, Sande CJ, Scarselli E, Capone S, Vitelli A, Nicosia A, Silva-Reyes [...]Read more
- Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast laneOriginally published on Expert Rev Vaccines. 2017 Dec 16(12):1241-1252. Vitelli A, Folgori A, Scarselli E, Colloca S, Capone S, Nicosia A.Read more
- Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infectionsOriginally published on Sci Transl Med. 2015 Aug 12;7(300):300ra127. Taylor G, Thom M, Capone S, Pierantoni A, Guzman E, Herbert R, Scarselli E, Napolitano F, Giuliani A, Folgori A, Colloca S, [...]Read more